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Protocol
AbstrACt
Introduction The STRoke Interactive Virtual thErapy 
(STRIVE) intervention provides community-dwelling stroke 
survivors access to individualised, remotely supervised 
progressive exercise training via an online platform. This 
trial aims to determine the clinical efficacy of the STRIVE 
intervention and its effect on brain activity in community-
dwelling stroke survivors.
Methods and analysis In a multisite, assessor-blinded 
randomised controlled trial, 60 stroke survivors >3 
months poststroke with mild-to-moderate upper extremity 
impairment will be recruited and equally randomised by 
location (Melbourne, Victoria or Launceston, Tasmania) 
to receive 8 weeks of virtual therapy (VT) at a local 
exercise training facility or usual care. Participants 
allocated to VT will perform 3–5 upper limb exercises 
individualised to their impairment severity and preference, 
while participants allocated to usual care will be asked 
to maintain their usual daily activities. The primary 
outcome measures will be upper limb motor function 
and impairment, which will be assessed using the Action 
Research Arm Test and Upper Extremity Fugl-Meyer, 
respectively. Secondary outcome measures include upper 
extremity function and spasticity, as measured by the box 
and block test and Modified AshworthScale, respectively, 
and task-related changes in bilateral sensorimotor cortex 
haemodynamics during hand reaching and wrist extension 
movements as measured by functional near-infrared 
spectroscopy. Quality of life will be measured using the 
Euro-Quality of Life-5 Dimension-5 Level Scale, and the 
Motor Activity Log-28 will be used to measure use of the 
hemiparetic arm. All measures will be assessed at baseline 
and immediately postintervention.
Ethics and dissemination The study was approved by 
the Deakin University Human Research Ethics Committee 
in May 2017 (No. 2017–087). The results will be 
disseminated in peer-reviewed journals and presented at 
major international stroke meetings.
trial registration number ACTRN12617000745347; Pre-
results.
IntroduCtIon 
Stroke is one of the leading causes of adult 
disability in Western countries,1 and for 
many stroke survivors, upper extremity (UE) 
paresis makes performing activities of daily 
living (ADLs) difficult. Up to 60% of commu-
nity-dwelling stroke survivors live with severe 
motor impairments of the shoulders, elbows 
and/or wrists that significantly impacts 
their functional capacity and quality of life.2 
Improved UE function is considered a reha-
bilitation priority after stroke,3 yet optimal 
recovery of arm function is poor.2 4 A large 
majority of stroke survivors experience a 
lack of support and access to rehabilitative 
services once they are discharged into the 
community,5 6 which can compromise their 
recovery. While most recovery occurs in the 
first weeks to months after stroke, improve-
ments in function can still be experienced 
beyond this period.7 
The use of virtual reality as a therapy, which 
is characterised by the participant being 
immersed in, and interacting with, a comput-
er-generated environment,8 is emerging as an 
efficacious treatment for UE impairment after 
stroke.9 10 Online virtual therapy (VT) systems 
can provide the fundamental elements 
needed for motor skill development; they 
can be individually tailored, involve many 
task-specific repetitions that are increasingly 
strengths and limitations of this study
 ► Community-based access allows for greater 
community engagement and real-world 
translatability than in a controlled laboratory 
environment.
 ► The STRoke Interactive Virtual thErapy (STRIVE) 
trial allows experimenters to remotely access and 
control virtual therapy exercise programmes based 
on the participant’s weekly performance data.
 ► Clinical and neurophysiological measures will 
determine functional and associated cortical 
changes in response to virtual therapy poststroke.
 ► While STRIVE is a community-based intervention, 
the trial is only accessible to participants that are 
mobile and can travel to the trial sites.
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challenging in response to participant improvement and 
feedback can be embedded in the system. The enriched 
environment offered by VT is thought to be effective 
in training problem solving and functional task perfor-
mance11 and can potentially increase participant engage-
ment compared with non-VT rehabilitation platforms.12
Online VT systems have the potential to address the 
lack of community-based rehabilitation support expe-
rienced by stroke survivors by being affordable, acces-
sible, user-friendly and importantly, have the ability to 
remotely monitor rehabilitation progress. VT systems, 
such as the Jintronix Rehabilitation System (Montreal, 
Canada) to be used in this study, can be administered 
affordably through commercially available products 
that include motion capture capabilities (eg, Microsoft 
Xbox Kinect V.2) and personal computers.13 Online VT 
systems can be easily implemented at a local community 
centre, which would enable patients with stroke to receive 
specialised treatment and monitoring remotely. Online 
VT platforms have been shown to be user-friendly and 
motivating,14 including interfaces that are engaging and 
easy to interact with, and software that can be run on any 
personal computer/device. In a Cochrane review, Laver et 
al9 reported low-quality evidence suggesting VT is a more 
effective approach to improve arm function after stroke 
compared with conventional therapy.9 A recent multiple 
systematic review, including 10 randomised controlled 
trials and four systematic reviews, found VT therapy to 
be similar to standard rehabilitation for treatment of UE 
impairment and disabilities.15
To understand the effects of VT on cerebral activity in 
stroke rehabilitation, neuroimaging techniques such as 
functional MRI (fMRI) have been used previously to deter-
mine cortical reorganisation postrehabilitation.16 While 
fMRI is considered the gold-standard measure in neuroim-
aging, these techniques may be limited as they only allow 
for small movements to occur within the scanner that are 
very different from activities of daily living (ADLs). In this 
sense, functional near-infrared spectroscopy (fNIRS) may 
be a more suitable neuroimaging technique as it is able 
to measure changes in cerebral haemodynamic responses 
(ie, changes in oxyhaemoglobin and deoxyhaemoglobin 
(HbO2 and HHb)) in response to larger body and head 
movements that mimic ADLs. Previous studies have 
also established that cerebral haemodynamic measures 
from fNIRS are highly comparable with blood oxygen-
level dependent signals from fMRI,17 18 which makes it 
a suitable surrogate to measure changes in brain activity 
following VT rehabilitation in people with stroke.
Given the advantages of increased accessibility to special-
ised treatment and monitoring that is afforded by VT, we 
aim to determine if an online VT system can provide effi-
cacious UE rehabilitation for community-dwelling stroke 
survivors. We have chosen to focus our intervention on 
UE function as impaired arm function is highly common 
after stroke,2 which profoundly impacts the capacity to 
Figure 1 The CONSORT 2010 flow diagram for the study. CONSORT, Consolidated Standards of Reporting Trials.
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perform ADLs19 and only a small number of stroke survi-
vors experience complete functional recovery of the UE.20
MEthods And AnAlysIs
study design
This is a multisite, assessor-blinded randomised 
controlled trial to be conducted in two Australian centres 
(Melbourne, Victoria and Launceston, Tasmania). The 
Consolidated Standards of Reporting Trials (CONSORT) 
statement (figure 1) has been used to guide trial design.21 
The trial will be reported according to the Standard 
Protocol Items: Recommendations for Interventional 
Trials (SPIRIT) guidelines22 and the Template for Inter-
vention Description and Replication.23
Participants
Community-dwelling stroke survivors will be recruited 
to participate from the Melbourne metropolitan area, 
Victoria, and from Launceston, Tasmania. The study will 
be advertised on the Australian Stroke Foundation and 
Heart Foundation websites, through social media (eg, 
twitter and facebook), in local newspapers and at local 
community centres.
Potential participants will initiate contact with the 
research team by responding to the study advertisements 
by phone or email. The researchers will respond in kind 
and provide information about the project, and then 
send an electronic or paper copy of the plain language 
statement to the participant. All potential participants 
will then attend an initial screening session at Deakin 
University, Burwood, Melbourne or the University of 
Tasmania, Launceston, to determine their eligibility to 
participate according to the inclusion/exclusion criteria. 
Participants will be included if they are (1) above the 
age of 18 years, (2) community-dwelling stroke survivors, 
(3) with mild-to-moderate UE impairments (Fugl-Meyer 
Upper Extremity (UE-FM) Score 25–45), (4) no cognitive 
impairments (Mini Mental State Examination Score >24), 
(5) at least 3 months poststroke, (6) can demonstrate 
an observable motor-evoked potential from the resting 
paretic hand, of at least 0.05 mV, in 5 out 10 trials during 
transcranial magnetic stimulation and (7) able to read 
English. Participants will be excluded from the study if 
they have (1) other neurological conditions (eg, Parkin-
son’s disease or dementias), (2) no observable movements 
in shoulders or elbows and (3) upper extremity joint pain 
that would limit their ability to complete the trial.
If eligible, the principal investigator will provide the 
individual with a consent form to read and sign. The 
individual will be given the opportunity to ask the prin-
cipal investigator any questions about the study and 
their potential participation in it. On providing signed 
informed consent, all individuals will be scheduled for 
baseline and postintervention testing at Deakin Univer-
sity Physical Activity and Nutrition research laboratory 
(Burwood, Melbourne, Australia) or the University 
of Tasmania Exercise Physiology Clinic (Launceston, 
Tasmania, Australia).
randomisation and blinding
Following study enrolment and completion of the base-
line testing, participants will be randomised into a VT 
intervention or usual care (control; UC) group via a 
computerised random sequence generator and using a 
block randomisation design (according to location) and 
stratified by gender.
location and setting
The participants randomised to the VT group will under-
take training at the High Street Road Uniting Church 
(for the Melbourne-based participants) or the University 
Figure 2 Examples of VT therapy games that target UE mobility of the shoulders, elbows and wrists. UE, upper extremity; VT, 
Virtual therapy.
4 Johnson L, et al. BMJ Open 2018;8:e018388. doi:10.1136/bmjopen-2017-018388
Open Access 
of Tasmania Exercise Physiology Clinic, Launceston (for 
the Tasmanian-based participants). A Microsoft Xbox 
Kinect V.2 (Microsoft, Redmond, Washington, USA) 
and a laptop will be placed at each training location. All 
participants will be instructed to complete a daily physical 
activity diary throughout the study.
An exercise physiologist with at least 2  years of experi-
ence working with people with neurological impairments 
and/or brain injuries will be located at each training site 
to provide technical support on the VT system and docu-
ment any adverse events (AEs) . 
Intervention
The participants in the VT group will attend their local 
exercise training facility twice weekly, with each session 
separated by at least 24 hours, for eight consecutive weeks 
to complete the VT training. Each VT session will last 
approximately 45–60 min, which will equate to approxi-
mately 12– 16 hours of total therapy time across the dura-
tion of the study. This total amount of therapy is consistent 
with previous research as necessary to elicit improvements 
in motor function.9 Figure 2 contains examples of the UE 
exercises that will be used in this study.
The Jintronix Rehabilitation System (Montreal, 
Canada) to be used in this study will assess the partici-
pants active range of motion (ROM) of the shoulders, 
elbows and wrists, which will be used to establish the 
initial ROM of the exercises. The prescription of UE 
exercises will be determined by the researcher at the 
initial session. In the initial training session, the partici-
pants will be asked to provide feedback on their prefer-
ence and capacity to perform the prescribed exercises. If 
the participants report experiencing difficulties with the 
intensity and type of exercises prescribed, an alternative 
exercise, that still targets the intended muscle group and 
action, will be selected. The exercise type and intensity 
will be selected and tailored to target the individual’s UE 
impairment, which will be based on the individual’s base-
line function and active ROM of the shoulder, elbow and 
wrist. The Jintronix Rehabilitation System records each 
participant’s performance (ie, number of task repetitions, 
time in therapy for each exercise and task performance 
accuracy) for each session completed, and the training 
intensity for each participant will be modified according 
to their performance during the previous week. An 
advantage of the Jintronix Rehabilitation System is the 
capability of the system to adjust the training stimulus by 
changing the number of repetitions performed, and the 
ROM that the exercises are performed in, as the partici-
pant adapts over the duration of the intervention.
Any participants who are wheelchair users or have diffi-
culty standing for long periods may perform their exer-
cises while seated, with the Jintronix system capable of 
detecting UE movement in either a standing or seated 
position. Monitoring of the training programme and 
modification in exercise prescription will be performed 
remotely by an exercise physiologist at Deakin Univer-
sity at the end of each week via the clinician’s interface 
module of the Jintronix software. They will not have any 
direct contact with the participants, but will tailor each 
participant’s VT training in response to their adaptation 
to the programme. Progression of each exercise will be 
based on achievement of at least 80% success (ie, the 
participant is able to hit at least 8 out of 10 targets in a 
game) in exercise performance over two consecutive 
training sessions. The difficulty of the exercise will be 
progressed by 10%, which may consist of, but not limited 
to, more targets to hit, need for greater active ROM to 
successfully perform the task or quicker movement time 
to target. If a participant achieves a score of <50% in two 
consecutive exercise sessions for a particular exercise, 
the level of difficulty for that particular exercise will be 
reduced by 10%. 
Control
UC, in the context of this study, is defined as maintaining 
the level of physical activity similar to that prior to enrol-
ment into the trial. All participants allocated to the UC 
control group will be requested to maintain their daily 
routine and any existing therapy, and to report any 
change in the dose of their therapy. The UC group partic-
ipants will only be required to attend the testing sessions 
(outlined below) at baseline and after 8 weeks.
outcome measures
Table 1 shows the standard protocol items and outcome 
measures as recommended by the SPIRIT guidelines for 
interventional trials. A change in the Action Research 
Arm Test (ARAT) score and the UE-FM scale from prein-
tervention to postintervention will be joint primary 
outcomes in this study.
The ARAT is a measure of arm motor function that 
consists of 19 items grouped into four subscales: grasp, 
grip, pinch and gross movement.24 It uses ordinal scoring, 
with each item scored as either a 0 (‘cannot perform 
any part of the test’), 1 (‘performs the test partially’), 2 
(‘completes the test, but takes abnormally long time’) 
or 3 (‘performs the test normally’), with a lower score 
indicating reduced UE function.24 The ARAT has estab-
lished reliability25 26 and validity, is responsive to change27 
and has good concurrent validity compared with other 
measures used to assess arm motor function.28
The UE-FM assessment is a stroke-specific func-
tional performance measure that includes 33 ques-
tions (maximum score of 66) designed to assess muscle 
strength, reflexive activity and motor control.29 Each item 
is scored as either a 0 (‘unable to perform’), 1 (‘able to 
perform in part’) or 2 (‘able to perform’), with a lower 
score indicating reduced UE function.29 30 The UE-FM is a 
reliable and valid assessment of UE motor function,31 that 
is sensitive to change.32
Secondary outcome measures include the box and block 
test (BBT), which provides a measure of arm and hand 
function, and the Modified Ashworth Scale (MAS) score, 
which measures upper and lower limb spasticity. The 
Motor Activity Log-28 (MAL-28) and Euro-Quality of Life-5 
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Dimension-5 Level (EQ-5D-5L) Scale will be used to docu-
ment the daily use of the stroke-affected arm and how VT 
may impact on quality of life (QoL), respectively. fNIRS 
will be used to measure task-related changes in haemo-
dynamic responses of the bilateral primary sensorimotor 
cortices (SMCs).
The BBT is commonly used to measure unilateral gross 
motor dexterity of the arm and hand poststroke.33 During 
the BBT, participants will be seated at a table, facing a 
rectangular box that is partitioned into two square 
compartments of equal dimension. One hundred and 
fifty, 2.5 cm, coloured, wooden blocks are placed in one 
compartment, and the participant will be instructed to 
move as many blocks as possible, one at a time, to the 
other compartment in 60 s. The BBT is scored by counting 
the number of blocks carried over the partition from one 
compartment to the other during the 60 s trial period. 
In order to score a point, the participant’s hand must 
cross over the partition, and blocks that drop or bounce 
out of the second compartment onto the table or floor 
are still recorded as a point. Should multiple blocks be 
carried over at the same time, only a single point will be 
recorded. Higher scores on the test indicate better gross 
motor dexterity. Previous studies using the BBT in people 
with stroke have shown excellent test-retest reliability 
(ICC=0.96) and inter-rater reliability (ICC=0.99).34
The MAS is commonly used to measure the intensity 
of muscle spasticity experienced poststroke in the upper 
and lower extremities.35 Relevant muscle groups are 
passively moved about a joint and scored on a 0 (‘no 
increase in tone’) to 4 (‘affected part(s) rigid in flexion 
or extension’) scale, with a lower score indicating a lower 
resistance to movement (ie, reduced spasticity). The 
MAS has excellent inter-rater and intrarater reliability36 
and convergent validity with motor performance37 38 and 
neurophysiological measures.37
The MAL-28 is a stroke-specific self-report questionnaire 
that quantifies UE performance in real world activities.39 
The participant will be asked to rate their arm function 
each week according to two subscales: the Quality of 
Movement (QOM) scale and the Amount of Use (AOU) 
scale. Each scale is rated on a scale of 0 (‘the weaker arm 
was not used at all for that activity’ on the QOM scale, and 
‘did not use my weaker arm’ on the AOU scale) to 5 (‘the 
ability to use the weaker arm for that activity was as good 
as before the stroke’ on the QOM and ‘used my weaker 
arm as often as before the stroke’ on the AOU scale).39 
Scores on each scale are calculated as the mean of the 
scored items attempted with the affected arm, with a 
higher average score indicative of better QOM and more 
use of the weaker arm.
The EQ-5D-5L provides an assessment of health-related 
QoL after stroke across five dimensions: mobility, self-care, 
usual activities, pain/discomfort and anxiety/depres-
sion.40 Each dimension is divided into 5 levels of perceived 
problems: no problems (level 1), slight problems (level 
2), moderate problems (level 3), severe problems (level 
4) and extreme problems (level 5). The participant will 
be asked to indicate their health state by ticking the box 
corresponding to the most appropriate statement in each 
of the five dimensions. Once all five dimensions have been 
scored, the digits for the five dimensions are combined 
Table 1 Standard Protocol Items: Recommendations for Interventional Trials22
Study period
Enrolment Preallocation Postallocation
Time point −t1 t1 t2
Enrolment
  Eligibility screen X
  Informed consent X
  Randomisation X
Intervention
  Virtual therapy
  Usual care
Assessment
  Action Research Arm Test X X
  Fugl-Meyer Upper ExtremityAssessment X X 
  Modified Ashworth Scale X X 
  Mini-Mental State Examination X X 
  Functional near-infrared spectroscopy X X
  EQ-5D-5L X X
  Box and block test X X
  Motor activity log-28 X X
EQ-5D-5L, Euro-Quality of life-5 Dimension-5 Level. 
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into a 5-digit number that describes the patient’s health 
state. Lower scores indicate a higher QoL. The EQ-5D-5L 
is a valid measure of health-related QoL after stroke,40 
with acceptable responsiveness.41
fNIRS is a non-invasive and portable optical neuroim-
aging technique that can measure task-related changes 
in cortical haemodynamics (ie, an indirect measure of 
cortical activation) in stroke survivors,42 but without 
the large costs and non-portability of fMRI assessments. 
fNIRS has previously been used to measure changes in 
prefrontal cortical activation during a virtual reality move-
ment task in healthy individuals.43 In this study, fNIRS 
will be used to measure bilateral SMC activation during 
functional seated hand reaching and wrist extension 
movement tasks of the paretic and non-paretic arm. The 
assessment of these motor task-related bilateral SMC acti-
vation changes after the STRIVE intervention will provide 
a cortical correlate of the change in motor function,44 as 
quantified using the Kinect V.2 with the Macoki software 
(NaturalPad, Montpellier, France).45
Compliance and safety monitoring
The VT system provides information on usage time during 
each training session, which will be remotely monitored 
as a measure of exercise compliance. In addition, the 
attending exercise physiologist will record the partici-
pant’s attendance. Should a participant miss a training 
session, they will be contacted by the attending exercise 
physiologist and the reason for their absence will be docu-
mented. If more than one training session is missed, a 
make-up session will be scheduled. The attending exer-
cise physiologist will also document and handle any AEs 
(ie, muscle or joint pain, syncope, falls and injuries) or 
serious adverse events (SAEs, ie, any incident requiring 
hospitalisation).46 The study is voluntary and partici-
pants can discontinue the study on request at any time, 
or if there is a change in health status (ie, worsening of 
function or overall health) or in the event of an AE or 
SAE. All AEs and SAEs experienced by the study partici-
pants during the trial will be reported immediately to the 
principal investigator and the Deakin University Human 
Research Ethics Committee. Should any participant suffer 
from any AE or SAE because of this trial, ancillary support 
and/or post-trial care will be provided.
sample size estimation
To successfully detect a minimal clinically important 
difference in the UE-FM score of 6.4%–11% (an increase 
of 4.25–7.25 points out of 66),47 30 participants in each 
group (VT and UC) will be sufficient to provide 80% 
power (95% CI) and account for a 30% dropout rate.
statistical analysis plan
Mixed factorial analysis of variance will be used to deter-
mine the difference in clinical and neurophysiological 
measures across GROUP (VT vs Control) and TIME 
(PREINTERVENTION vs POSTINTERVENTION). 
Bonferroni post hoc t-tests for multiple comparisons will 
be used to determine where significance has occurred. 
Significance will be set at P<0.05.
EthICs And dIssEMInAtIon
The primary results regarding the efficacy of the 
STRIVE intervention to improve UE function and 
spasticity, and QoL poststroke will be published in a 
peer-reviewed journal and presented at an international 
conference. Separate manuscripts will be written for the 
neurobiological secondary outcome measures. These 
will also be submitted for publication in peer-reviewed 
journals and presented at appropriate conferences. A 
summary of the main findings of the study will be made 
available to the participants involved in the study, and 
the Heart Foundation who have funded this study. All 
personal data of potential and enrolled participants will 
be deidentified and stored in a locked filing cabinet (phys-
ical documents) and password-protected work computer 
(participant’s results and relevant softcopy documents) 
for a minimum of 5 years with the principal investigator. 
Should there be any changes to the protocol (ie, eligi-
bility criteria, outcomes, analyses or project extension), 
an ethics amendment form will be submitted to DUHREC 
for consideration and approval.
Following completion of the study and publication 
of the findings, all data will be deposited in the Deakin 
University data repository and made freely available on 
request to the corresponding author.
dIsCussIon
Despite adequate inpatient rehabilitation support, and 
evidence that indicates functional improvements can 
be made many months poststroke,3 optimal recovery 
of UE function is poor.2 While stroke survivors are 
strongly advised to continue with physical rehabilita-
tion on discharge into the community, they often face 
a lack of support and access to rehabilitative services. 
The STRIVE study will investigate the effectiveness of 
VT therapy compared with UC in reducing UE impair-
ment after stroke.
The STRIVE intervention is designed to offer stroke 
survivors individualised therapy, featuring highly repet-
itive task-specific movements, prescriptive feedback and 
progression within an enriched environment. The Jintr-
onix Rehabilitation System is highly modifiable and 
adaptive to the abilities of the user—a critical feature 
given the expected variability in the stroke cohort.
The clinically oriented primary (ie, ARAT and 
UE-FM) and secondary (ie, BBT and MAS) outcomes 
of the STRIVE study will assess the efficacy of VT reha-
bilitation in modifying arm function and spasticity. The 
MAL-28 and EQ-5D-5L assessments will indicate the 
impact of the STRIVE intervention on the functional 
ability and QoL of the participants. Furthermore, the 
secondary outcome of fNIRS neuroimaging will provide 
an insight into VT-mediated neuroplastic changes in 
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the bilateral SMC that will aid in furthering our under-
standing of the central adaptations implicated in UE 
motor function recovery.
The strengths of the STRIVE study include the 
tailored approach to the initial therapy prescription, 
and also the responsiveness of the intervention to 
meet the changing abilities of the user over the dura-
tion of the intervention. The attendance of an exer-
cise physiologist at the therapy sessions aims to address 
a common complaint by users of technology-based 
therapy, that is, the challenge in setting up the tech-
nology and problem-solving technical issues. It also is a 
pragmatic approach to ensure the safety of the partic-
ipants. Furthermore, the Microsoft Xbox Kinect V.2 is 
a commercially-available device that can be set-up at a 
very low cost and is compatible with devices commonly 
found in a local community centre, making it a highly 
accessible device.
The STRIVE study will afford community-dwelling 
stroke survivors the opportunity for supported access to 
rehabilitation. Our findings will assist clinicians in the 
prescription of efficacious rehabilitation for patients 
using a low-cost, online VT platform that can be imple-
mented into a community setting and integrated into 
the user’s daily life. This may lower the burden of 
disease by ensuring stroke survivors can receive special-
ised treatment and monitoring from within their local 
community beyond the initial phase of stroke recovery, 
which may improve rehabilitation compliance and 
outcomes in the long term.
Author affiliations
1Stroke Division, The Florey Institute of Neuroscience and Mental Health, University 
of Melbourne, Heidelberg, Victoria, Australia
2Faculty of Health Sciences, Australian Catholic University, Melbourne, Australia
3Institute of Sport, Exercise and Active Living (ISEAL), Victoria University, Melbourne, 
Australia
4Faculty of Health, School of Health Sciences, University of Tasmania, Launceston, 
Tasmania, Australia
5Department of Physical Therapy, University of British Columbia and the 
Rehabilitation Research Program, GF Strong Rehabilitation Centre, University of 
British Columbia, Vancouver, Canada
6EuroMov, University of Montpellier, Montpellier, France
7Cognitive Neuroscience Unit, School of Psychology, Deakin University, Burwood, 
Victoria, Australia
8SilverLine Research Services, Brisbane, Australia
9Institute for Physical Activity and Nutrition (IPAN), School of Exercise and Nutrition 
Sciences, Deakin University, Burwood, Victoria, Australia
Acknowledgements We would like to thank Ms Jessica Freeman and Ms Karima 
Bakhti for their assistance in developing the study. Ms Freeman has provided 
consent for her image to be published in figure 2. 
Contributors W-PT, LJ, MM and M-LB: were involved in conception and trial 
design. LJ: wrote the first draft of this manuscript. W-PT, LJ, MM and M-LB: were 
involved in critical revision of the article for important intellectual content. All the 
authors were involved in final approval of the article.
Funding This work was supported by a Heart Foundation Vanguard Grant 
(101350). W-PT is supported by an Alfred Deakin Postdoctoral Research Fellowship. 
MM was supported by Silverline research services. 
Competing interests None declared.
Ethics approval Deakin University Human Research Ethics Committee (DUHREC, 
no. 2017–087).
Provenance and peer review Not commissioned; externally peer reviewed.
open Access This is an Open Access article distributed in accordance with the 
Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which 
permits others to distribute, remix, adapt, build upon this work non-commercially, 
and license their derivative works on different terms, provided the original work is 
properly cited and the use is non-commercial. See: http:// creativecommons. org/ 
licenses/ by- nc/ 4. 0/
© Article author(s) (or their employer(s) unless otherwise stated in the text of the 
article) 2018. All rights reserved. No commercial use is permitted unless otherwise 
expressly granted.
rEFErEnCEs
 1. Feigin VL, Krishnamurthi RV, Parmar P, et al. Update on the global 
burden of ischemic and hemorrhagic stroke in 1990-2013: The GBD 
2013 study. Neuroepidemiology 2015;45:161–76.
 2. Kwakkel G, Kollen BJ, van der Grond J, et al. Probability of regaining 
dexterity in the flaccid upper limb: impact of severity of paresis and 
time since onset in acute stroke. Stroke 2003;34:2181–6.
 3. Barker RN, Gill TJ, Brauer SG. Factors contributing to upper limb 
recovery after stroke: a survey of stroke survivors in Queensland 
Australia. Disabil Rehabil 2007;29:981–9.
 4. Brauer SG, Hayward KS, Carson RG, et al. The efficacy of SMART 
Arm training early after stroke for stroke survivors with severe upper 
limb disability: a protocol for a randomised controlled trial. BMC 
Neurol 2013;13:71.
 5. Pollack MR, Disler PB. Rehabilitation of patients after stroke. Med J 
Aust 2002;177:452–6.
 6. Stroke Foundation. National stroke audit – rehabilitation services 
report. Melbourne, Australia: Stroke Foundation, 2016.
 7. Teasell RW, Murie Fernandez M, McIntyre A, et al. Rethinking 
the continuum of stroke rehabilitation. Arch Phys Med Rehabil 
2014;95:595–6.
 8. Weiss PL, Kizony R, Feintuch U, et al. Virtual reality in 
neurorehabilitation. In: Selzer M, Cohen L, Gage F, Clarke S, et 
al. eds. Textbook of neural repair and rehabilitation: Cambridge 
University Press, 2006:182–97.
 9. Laver KE, George S, Thomas S, et al. Virtual reality for stroke 
rehabilitation. Cochrane Database Syst Rev 2015:CD008349.
 10. Teo WP, Muthalib M, Yamin S, et al. Does a combination of virtual 
reality, neuromodulation and neuroimaging provide a comprehensive 
platform for neurorehabilitation? - a narrative review of the literature. 
Front Hum Neurosci 2016;10:284.
 11. Risedal A, Mattsson B, Dahlqvist P, et al. Environmental influences 
on functional outcome after a cortical infarct in the rat. Brain Res Bull 
2002;58:315–21.
 12. Laut J, Cappa F, Nov O, et al. Increasing patient engagement in 
rehabilitation exercises using computer-based citizen science. PLoS 
One 2015;10:e0117013.
 13. Bird ML, Cannell J, Callisaya ML, et al. “FIND Technology”: 
investigating the feasibility, efficacy and safety of controller-free 
interactive digital rehabilitation technology in an inpatient stroke 
population: study protocol for a randomized controlled trial. Trials 
2016;17:203.
 14. Lloréns R, Noé E, Colomer C, et al. Effectiveness, usability, and 
cost-benefit of a virtual reality-based telerehabilitation program for 
balance recovery after stroke: a randomized controlled trial. Arch 
Phys Med Rehabil 2015;96:418–25.
 15. Hatem SM, Saussez G, Della Faille M, et al. Rehabilitation of 
motor function after stroke: a multiple systematic review focused 
on techniques to stimulate upper extremity recovery. Front Hum 
Neurosci 2016;10:442.
 16. You SH, Jang SH, Kim YH, et al. Virtual reality-induced cortical 
reorganization and associated locomotor recovery in chronic stroke: 
an experimenter-blind randomized study. Stroke 2005;36:1166–71.
 17. Anwar AR, Muthalib M, Perrey S, et al. Effective connectivity of 
cortical sensorimotor networks during finger movement tasks: a 
simultaneous fNIRS, fMRI, EEG study. Brain Topogr 2016;29:645–60.
 18. Muthalib M, Anwar AR, Perrey S, et al. Multimodal integration 
of fNIRS, fMRI and EEG neuroimaging. Clin Neurophysiol 
2013;124:2060–2.
 19. Pollock A, Farmer SE, Brady MC, et al. Interventions for improving 
upper limb function after stroke. Cochrane Database Syst Rev 
2014:CD010820.
 20. Nakayama H, Jørgensen HS, Raaschou HO, et al. Recovery of upper 
extremity function in stroke patients: the Copenhagen stroke study. 
Arch Phys Med Rehabil 1994;75:394–8.
8 Johnson L, et al. BMJ Open 2018;8:e018388. doi:10.1136/bmjopen-2017-018388
Open Access 
 21. Moher D, Schulz KF, Altman DG. The CONSORT statement: revised 
recommendations for improving the quality of reports of parallel-
group randomised trials. Lancet 2001;357:1191–4.
 22. Chan AW, Tetzlaff JM, Altman DG, et al. SPIRIT 2013 statement: 
defining standard protocol items for clinical trials. Ann Intern Med 
2013;158:200–7.
 23. Hoffmann TC, Glasziou PP, Boutron I, et al. Better reporting of 
interventions: template for intervention description and replication 
(TIDieR) checklist and guide. BMJ 2014;348:g1687.
 24. Lyle RC. A performance test for assessment of upper limb function 
in physical rehabilitation treatment and research. Int J Rehabil Res 
1981;4:483–92.
 25. Hsieh CL, Hsueh IP, Chiang FM, et al. Inter-rater reliability and 
validity of the action research arm test in stroke patients. Age Ageing 
1998;27:107–13.
 26. Van der Lee JH, De Groot V, Beckerman H, et al. The intra- and 
interrater reliability of the action research arm test: a practical test 
of upper extremity function in patients with stroke. Arch Phys Med 
Rehabil 2001;82:14–19.
 27. Lang CE, Wagner JM, Dromerick AW, et al. Measurement of upper-
extremity function early after stroke: properties of the action research 
arm test. Arch Phys Med Rehabil 2006;87:1605–10.
 28. Lin JH, Hsu MJ, Sheu CF, et al. Psychometric comparisons of 4 
measures for assessing upper-extremity function in people with 
stroke. Phys Ther 2009;89:840–50.
 29. Deakin A, Hill H, Pomeroy VM. Rough guide to the Fugl-Meyer 
assessment: upper limb segment. Physiotherapy 2003;89:751–63.
 30. Singer B, Garcia-Vega J. The Fugl-Meyer upper extremity scale. J 
Physiother 2017;63:53.
 31. Gladstone DJ, Danells CJ, Black SE. The Fugl-Meyer assessment 
of motor recovery after stroke: a critical review of its measurement 
properties. Neurorehabil Neural Repair 2002;16:232–40.
 32. Hsieh YW, Wu CY, Lin KC, et al. Responsiveness and validity of 
three outcome measures of motor function after stroke rehabilitation. 
Stroke 2009;40:1386–91.
 33. Desrosiers J, Bravo G, Hébert R, et al. Validation of the box and 
block test as a measure of dexterity of elderly people: reliability, 
validity, and norms studies. Arch Phys Med Rehabil 1994;75:751–5.
 34. Platz T, Pinkowski C, van Wijck F, et al. Reliability and validity of arm 
function assessment with standardized guidelines for the Fugl-Meyer 
test, action research arm test and box and block test: a multicentre 
study. Clin Rehabil 2005;19:404–11.
 35. Bohannon RW, Smith MB. Interrater reliability of a modified Ashworth 
scale of muscle spasticity. Phys Ther 1987;67:206–7.
 36. Gregson JM, Leathley MJ, Moore AP, et al. Reliability of 
measurements of muscle tone and muscle power in stroke patients. 
Age Ageing 2000;29:223–8.
 37. Katz RT, Rovai GP, Brait C, et al. Objective quantification of spastic 
hypertonia: correlation with clinical findings. Arch Phys Med Rehabil 
1992;73:339–47.
 38. Lin FM, Sabbahi M. Correlation of spasticity with hyperactive stretch 
reflexes and motor dysfunction in hemiplegia. Arch Phys Med 
Rehabil 1999;80:526–30.
 39. Uswatte G, Taub E, Morris D, et al. The motor activity Log-28: 
assessing daily use of the hemiparetic arm after stroke. Neurology 
2006;67:1189–94.
 40. Golicki D, Niewada M, Buczek J, et al. Validity of EQ-5D-5L in stroke. 
Qual Life Res 2015;24:845–50.
 41. Chen P, Lin KC, Liing RJ, et al. Validity, responsiveness, and minimal 
clinically important difference of EQ-5D-5L in stroke patients 
undergoing rehabilitation. Qual Life Res 2016;25:1585–96.
 42. Mihara M, Miyai I. Review of functional near-infrared spectroscopy in 
neurorehabilitation. Neurophotonics 2016;3:031414.
 43. Basso Moro S, Bisconti S, Muthalib M, et al. A semi-immersive virtual 
reality incremental swing balance task activates prefrontal cortex: a 
functional near-infrared spectroscopy study. Neuroimage 2014;85(Pt 
1):451–60.
 44. Lin PY, Chen JJ, Lin SI. The cortical control of cycling 
exercise in stroke patients: an fNIRS study. Hum Brain Mapp 
2013;34:2381–90.
 45. Bakhti K, Muthalib M, Perrey S, et al. fNIRS provides clues about the 
neural correlates of the learned non-use of the paretic arm after a 
stroke. Ann Phys Rehabil Med 2016;59:e77–e78.
 46. Wallace S, Myles PS, Zeps N, et al. Serious adverse event 
reporting in investigator-initiated clinical trials. Med J Aust 
2016;204:231–3.
 47. Page SJ, Levine P, Hade E. Psychometric properties and 
administration of the wrist/hand subscales of the Fugl-Meyer 
Assessment in minimally impaired upper extremity hemiparesis in 
stroke. Arch Phys Med Rehabil 2012;93:2373–6.
